Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03567707 · ClinicalTrials.gov registry record · Early Phase 1
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
A Early Phase 1 study of Asthma and Allergic Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Early Phase 1
- Development phase
- 114
- Enrollment target
- 2
- Study locations
NCT03567707 is a Early Phase 1 study of Asthma and Allergic Diseases that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 114 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03567707, a Early Phase 1 study of Asthma and Allergic Diseases, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 114 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to assess at how differences in the microbiome (naturally occurring bacteria) of a baby may protect, or put a baby at risk, for allergic problems. The microbiome refers to the thousands of bacteria and molds that live in and on our bodies. The microbiome plays an important role in our health. Differences in the microbiome can affect our immune system in ways that might make some people more likely to get allergies and asthma. Early life events and exposures are very important for establishing the human microbiome. The newborn baby's microbiome changes very quickly during the first weeks and months of life. There is information that suggests C-section birth is associated with higher risk of certain diseases, including allergies and asthma. Some researchers think one reason for this is that passing through the mother's vaginal canal during birth exposes the baby to bacteria that promote healthy immune system development, something that C-section babies don't get. Transferring these potentially beneficial vaginal bacteria to C-section babies may help prevent some diseases later.
Conditions Studied
Interventions
- OTHER Standard care
- DRUG Vaginal seeding
- DRUG Placebo Seeding
- OTHER Post-seeding Care
Study Locations (2)
New York
- Mount Sinai West - New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2027-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03567707
The ClinicalTrials.gov registry entry for NCT03567707 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Standard care is the first listed.
NCT03567707 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03567707 about?
NCT03567707 is a clinical study titled "Vaginal Microbiome Exposure and Immune Responses in C-section Infants". The purpose of this research study is to assess at how differences in the microbiome (naturally occurring bacteria) of a baby may protect, or put a baby at risk, for allergic problems. The microbiome refers to the thousands of bacteria and molds that live in and on our bodies. The microbiome plays a...
What is the current status of trial NCT03567707?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 114 participants. The study started on 2018-11-28. Estimated completion is 2027-01.
What conditions does trial NCT03567707 study?
This clinical trial studies the following conditions: Asthma, Allergic Diseases.
What interventions are being tested in trial NCT03567707?
The interventions under investigation include: Standard care (OTHER), Vaginal seeding (DRUG), Placebo Seeding (DRUG), Post-seeding Care (OTHER).
Who is sponsoring clinical trial NCT03567707?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03567707 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions
COMPLETED · Early Phase 1
-
Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions
COMPLETED · Early Phase 1
-
The Leaky Lung Test
COMPLETED · Early Phase 1
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.